# **1** Deep learning predicts HRD and platinum response from histology slides in

### 2 breast and ovarian cancer

- 3 Erik N. Bergstrom<sup>1-3</sup>, Ammal Abbasi<sup>1-3</sup>, Marcos Díaz-Gay<sup>1-3</sup>, Loïck Galland<sup>4-7</sup>, Scott M.
- 4 Lippman<sup>1</sup>, Sylvain Ladoire<sup>4-7</sup>, and Ludmil B. Alexandrov<sup>1-3\*</sup>
- 5

### 6 Affiliations:

- <sup>7</sup> <sup>1</sup>Moores Cancer Center, UC San Diego, La Jolla, CA, 92037, USA
- <sup>2</sup>Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, 92093, USA
- <sup>3</sup>Department of Bioengineering, UC San Diego, La Jolla, CA, 92093, USA
- 10 <sup>4</sup>Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
- <sup>5</sup>Platform of Transfer in Biological Oncology, Centre Georges-François Leclerc, Dijon, France
- 12 <sup>6</sup>University of Burgundy-Franche Comté, France
- 13 <sup>7</sup>Centre de Recherche INSERM LNC-UMR1231, Dijon, France
- 14
- <sup>\*</sup>Correspondence should be addressed to <u>L2alexandrov@health.ucsd.edu</u>.

### 16 ABSTRACT

Breast and ovarian cancers harboring homologous recombination deficiencies (HRD) can benefit 17 18 from platinum-based chemotherapies and PARP inhibitors. Standard diagnostic tests for 19 detecting HRD utilize molecular profiling, which is not universally available especially for 20 medically underserved populations. Here, we trained a deep learning approach for predicting 21 genomically derived HRD scores from routinely sampled hematoxylin and eosin (H&E)-stained 22 histopathological slides. For breast cancer, the approach was externally validated on three 23 independent cohorts and allowed predicting patients' response to platinum treatment. Using 24 transfer learning, we demonstrated the method's clinical applicability to H&E-images from high-25 grade ovarian tumors. Importantly, our deep learning approach outperformed existing genomic 26 HRD biomarkers in predicting response to platinum-based therapies across multiple cohorts, 27 providing a complementary approach for detecting HRD in patients across diverse 28 socioeconomic groups. 29

30 One-Sentence Summary: A deep learning approach outperforms molecular tests in predicting
31 platinum response of HRD cancers from histological slides.

### 32 MAIN TEXT

Precision oncology aims to personalize cancer therapy by first identifying and, subsequently, 33 34 targeting molecular defects in tumors within each individual (1). Many cancers harbor failures of 35 specific DNA repair pathways and utilizing synthetic lethal relationships amongst peripheral 36 pathways has proven an effective treatment approach (2). Previous mechanistic studies and 37 clinical trials have shown that breast and ovarian cancers harboring homologous recombination 38 DNA repair deficiency (HRD) are highly sensitive to platinum salts and poly (ADP-ribose) 39 polymerase (PARP) inhibitors (3). Historically, HRD has been associated with germline 40 mutations in specific genes leading to an increased cancer risk with the most notable 41 susceptibility genes being BRCA1 (4) and BRCA2 (5). In addition to germline variants, somatic 42 mutations and epigenetic dysregulation can also lead to HRD (6). Importantly, HRD cancers 43 exhibit characteristic patterns of somatic mutations (6-10) and gene expression (11, 12), and 44 these patterns have been leveraged as predictive biomarkers for targeted response to platinum 45 therapy and PARP inhibitors. Notably, the pattern of single-base substitution signature 3 (SBS3), part of the Catalogue of Somatic Mutations in Cancer (COSMIC) catalog of mutational 46 47 signatures (13), was previously utilized as a clinical biomarker for detecting HRD (7, 14). 48 In the United States, the FDA has approved two HRD companion diagnostic (CDx) tests for 49 50 patients with ovarian and metastatic breast cancer (15). Myriad myChoice® CDx and

51 FoundationOne® CDx determine HRD by quantifying overall genomic instability in

52 combination with *BRCA1/2* status (*16*, *17*). Additionally, multiple research and CLIA-certified

53 HRD diagnostic tests have been developed (18) and utilized to characterize the prevalence of

54 HRD across different solid tumors (19-21). These studies have identified HRD as commonly

55	found in multiple refractory human cancers, including triple-negative breast cancer, high-grade
56	serous ovarian cancer, and pancreatic adenocarcinoma, as well as established the role of HRD-
57	targeted therapies with platinum salts and PARP inhibitors (16, 22-24). Currently, all existing
58	HRD diagnostic tests intrinsically rely on DNA and/or RNA profiling leading to clinical-
59	workflow bottlenecks largely attributed to the availability of sufficient tissue samples for
60	molecular assays as well as to time to decision making and overall cost (25-27). For example, the
61	cost of an FDA-approved or a CLIA-certified HRD test is several thousand dollars (27) and
62	results can take from 3 to 6 weeks (25). In turn, this has precluded the widespread utilization of
63	molecular diagnostics in standard therapy and clinical trials $(1)$ with a disproportionately high
64	effect on patients from underserved populations (15).
65	
05	
66	While the utilization of sequencing-based diagnostics is limited, tumor biopsies are routinely
	While the utilization of sequencing-based diagnostics is limited, tumor biopsies are routinely processed in clinical practice for the diagnosis of solid-tumors by light-microscopic
66	
66 67	processed in clinical practice for the diagnosis of solid-tumors by light-microscopic
66 67 68	processed in clinical practice for the diagnosis of solid-tumors by light-microscopic morphological review of tissue stained with hematoxylin and eosin (H&E) ( <i>26</i> ). Combined with
66 67 68 69	processed in clinical practice for the diagnosis of solid-tumors by light-microscopic morphological review of tissue stained with hematoxylin and eosin (H&E) ( <i>26</i> ). Combined with recent advances in computational pathology, deep learning artificial intelligence (AI)-based
66 67 68 69 70	processed in clinical practice for the diagnosis of solid-tumors by light-microscopic morphological review of tissue stained with hematoxylin and eosin (H&E) (26). Combined with recent advances in computational pathology, deep learning artificial intelligence (AI)-based models allow for both prognostic and diagnostic predictions using only digital H&E slides (28).
66 67 68 69 70 71	processed in clinical practice for the diagnosis of solid-tumors by light-microscopic morphological review of tissue stained with hematoxylin and eosin (H&E) (26). Combined with recent advances in computational pathology, deep learning artificial intelligence (AI)-based models allow for both prognostic and diagnostic predictions using only digital H&E slides (28). Here we introduce DeepHRD, a deep learning AI platform for detecting HRD from digitalized
66 67 68 69 70 71 71	processed in clinical practice for the diagnosis of solid-tumors by light-microscopic morphological review of tissue stained with hematoxylin and eosin (H&E) (26). Combined with recent advances in computational pathology, deep learning artificial intelligence (AI)-based models allow for both prognostic and diagnostic predictions using only digital H&E slides (28). Here we introduce DeepHRD, a deep learning AI platform for detecting HRD from digitalized H&E slides. We train and validate DeepHRD models on data from The Cancer Genome Atlas
66 67 68 69 70 71 72 73	processed in clinical practice for the diagnosis of solid-tumors by light-microscopic morphological review of tissue stained with hematoxylin and eosin (H&E) (26). Combined with recent advances in computational pathology, deep learning artificial intelligence (AI)-based models allow for both prognostic and diagnostic predictions using only digital H&E slides (28). Here we introduce DeepHRD, a deep learning AI platform for detecting HRD from digitalized H&E slides. We train and validate DeepHRD models on data from The Cancer Genome Atlas (TCGA) project and demonstrate their ability to detect HRD using external datasets. Importantly,

76

### 77 **RESULTS**

We implemented DeepHRD, a weakly supervised convolutional neural network architecture that 78 79 uses multiple instance learning (MIL; Fig. 1) for predicting HRD status from digital H&E slides (29-31). Specifically, for training DeepHRD, a soft label is assigned to each digital whole-slide 80 81 H&E image (WSI) based on an HRD score derived using sequencing or genotyping data from 82 the same cancer sample (Supplementary Materials). Further, all partitioned regions of that 83 WSI, termed, tiles, are assigned a weak label based upon the sample's classification. It is 84 assumed that all tiles within a negatively labeled sample are homologous recombination 85 proficient (HRP), whereas at least one tile must exhibit an HRD phenotype within a positively labeled sample. These assumptions allow the model to be trained using only a single 86 87 classification label for an entire WSI without the need for detailed manual annotations from a 88 pathologist, which currently do not exist for characterizing HRD.

89

90 DeepHRD is based on a multi-resolution decision designed to mimic the standard diagnostic protocol used by pathologists, which performs an initial prediction on a low magnification (*i.e.*, 91 5x magnification) and then automatically selects regions of interest (ROI) to perform a 92 93 secondary prediction on an enhanced magnification within ROIs (i.e., 20x magnification; Fig. 1a (30). Once fully trained, the model generates HRD predictions directly from digital tissues 94 95 slides without the need for genomic profiling (Fig. 1b). Further, DeepHRD maps individual tile 96 predictions back to the original WSI, which allows visualizing the relative importance of tissue 97 regions for the obtained predictions (Fig. 1b). The final model encompasses an ensemble of five 98 identical architectures, with each producing multi-resolution prediction scores. The average of 99 these scores is used to make a final prediction for each tissue slide. Importantly, DeepHRD

100 estimates epistemic uncertainty using Bayesian dropout during inference of a tissue slide to 101 calculate confidence intervals for the final model prediction (Supplementary Materials). The 102 confidence intervals are subsequently used to provide a computational diagnostic 103 recommendation (Fig. 1b). 104 105 DeepHRD models were trained and internally validated using data from 1,008 TCGA breast 106 cancers (32) with flash frozen (FF) slides and 1,055 TCGA breast cancers with formalin-fixed 107 paraffin-embedded (FFPE) slides (fig. S1). All samples had whole-exome sequencing and 108 microarray genotyping data for calculating a genomic HRD score (fig. S1). We trained 109 DeepHRD breast cancer models by separating the samples with: (i) 70% used for training; (ii) 110 15% for adjusting training parameters; and (iii) 15% held-out for testing the final model (Fig. 1a; 111 fig. S1). Two independent models were trained, one for FF and one for FFPE tissue slides 112 (Supplementary Materials). Prior to training, the number of HRD and HRP samples per breast 113 cancer subtype were balanced to prevent learning subtype specific histological features (fig. S1). 114 Each trained DeepHRD breast cancer model allows making a patient-level prediction using only 115 a single FF or FFPE digital slide. Specifically, DeepHRD predicts whether a breast cancer is 116 HRD or HRP, and it overlays an HRD probability mask to the digital slide, thus, allowing 117 subsequent pathological investigations (Fig. 1b).

118

The DeepHRD breast cancer FF model exhibited an overall performance with an AUC of 0.81
([0.77-0.85] 95% Confidence Interval (CI); Fig. 2a) on the held-out TCGA samples. The
generalizability of the FF model was externally validated by applying it to 116 primary breast

122 cancer slides from the Clinical Proteomic Tumor Analysis Consortium (37) and 419 primary

123	breast tumors from the Molecular Taxonomy of Breast Cancer International Consortium (38)
124	(fig. S2a) resulting in an AUC of 0.76 ([0.71-0.82] 95% CI; Fig. 2a). Notably, while HRD is
125	enriched in luminal B, basal-like, and Her2 enriched breast cancers (fig. S1a), DeepHRD was
126	able to distinguish HR deficiency and proficiency across all subtypes (Fig. 2b). The DeepHRD
127	breast cancer FFPE model exhibited an AUC of 0.81 ([0.77-0.86] 95% CI; Fig. 2c) on the held-
128	out TCGA samples, which was identical to the flash frozen model. These results indicate that the
129	fixation procedure and differences in staining coloration have minimal effects on the
130	performance of predicting HRD status directly from breast cancer tissue slides.
131	
132	Importantly, the FFPE model was capable of distinguishing metastatic breast cancers (MBCs),
133	part of an independent clinical cohort, that had a complete response to platinum chemotherapy
134	( $n=9$ ) from MBCs having only a partial or no response to treatment ( $n=68$ ) with an AUC of 0.76
135	([0.54-0.93] 95% CI; Fig. 2c; fig. S2b). Additionally, clinical response to platinum-based therapy
136	and progression-free survival were assessed using the Response Evaluation Criteria in Solid
137	Tumors, version 1.1 (RECIST 1.1; fig. S2b) (36). Separating the MBCs treated with platinum
138	based upon DeepHRD's prediction revealed a median progression-free survival of 14.4 months
139	for HRD patients and 3.9 months for HRP patients (p-value=0.0019, log-rank test). The model's
140	predictive value was consistent after correcting for breast cancer subtype, age of diagnosis, and
141	the genomic HRD score with a hazard ratio of 0.47 ([0.27-0.83] 95% CI; q-value=0.0087; Fig.
142	2d). Further, DeepHRD captured 7 of the 9 complete responders to platinum treatment. In
143	comparison, neither the separation based upon BRCA1/2 mutations nor detecting the HRD-
144	associated signature SBS3 resulted in a significant difference in progression-free survival (q-
145	value=0.13 and q=0.34, respectively; Fig. 2d). While the small sample size of BRCA1/2 mutated

tumors (~8% of MBCs) influenced the significance levels compared to wild-type tumors, the
predictions from DeepHRD captured 4-fold more platinum sensitive samples. Lastly, the tissue
slides from the MBC were digitalized using a Hamamatsu Photonics Nanozoomer system, while
all other cohorts were digitalized using an Aperios ScanScope system, further demonstrating the
generalizability of DeepHRD.

151

Ovarian cancer patients have traditionally received first-line platinum chemotherapies making 152 153 them ideal to evaluate whether HRD predictions from tissue slides may have a direct clinical 154 benefit. To test whether DeepHRD can be used for other cancer types, we trained an independent FF ovarian cancer model by performing transfer learning on the TCGA ovarian cancer cohort 155 156 (*n*=589) using the pretrained weights and biases generated from the FF breast cancer model with 157 the convolutional weights and biases frozen during training (Fig. 3a; fig. S1). A similar training 158 approach employed for the breast cancer models was utilized for the ovarian cancer model 159 (Supplementary Materials). To assess the ability of the DeepHRD ovarian model to separate 160 individuals benefiting from treatment with platinum chemotherapy, the model was applied to a 161 held-out set of 66 high-grade serous ovarian cancers that received treatment with first-line 162 platinum chemotherapy. Patients predicted to be HRD had a median survival of 4.6 years, while 163 those predicted to be HRP had a median survival of 3.2 years with a hazard ratio of 0.45 ([0.22-164 0.90] 95% CI; q-value=0.024) after correcting for the stage of the cancer, age, and the genomic 165 HRD score (Fig. 3b). In comparison, we observed a worse separation when using a base model 166 without transfer learning (HR=0.53 [0.26-1.07] 95% CI; q-value=0.076; Fig. 3c), suggesting that 167 the transfer learning provides a benefit when attempting to train AI-based approaches on smaller 168 datasets. Consistent with the breast cancer cohort, neither separation based on mutations in

- 169 BRCA1/2 nor detecting the HRD-associated signature SBS3 resulted in a significant difference in
- 170 survival (q-values>0.10; **Fig. 3***c*).

### 171 **DISCUSSION**

172 The development of DeepHRD prediction models for breast and ovarian cancers demonstrates 173 the practicality of deploying AI-based guidance into clinical diagnostics and precision medicine 174 workflows. Results across multiple external cohorts indicate that the platform is applicable to 175 routinely sampled tissue blocks and generalizable across different cancers, digital scanning 176 systems, and tissue fixation procedures. DeepHRD's performance was consistent across primary 177 and metastatic breast cancers and, by incorporating transfer learning, the model was also 178 applicable to serous ovarian cancer. Since HRD is a complementary biomarker guiding the use 179 of platinum therapies and an FDA-approved companion diagnostic for the use of PARP 180 inhibitors (15-17), the performance of our DeepHRD platform has direct implications for the 181 treatment of other cancer types with known HR-deficiencies (19), notably within pancreatic 182 adenocarcinomas. Despite clear benefit from first-line platinum therapy in HRD-positive patients 183 with this refractory disease, there is a 3 to 6 week turn-around for genomic testing which is not 184 appropriate for an advanced pancreatic cancer with a median progression-free survival of 6 185 months (25). Further, access to HRD genomic testing is even more limited in developing 186 countries (15). With increasing clinical evidence for the treatment of HRD tumors with platinum 187 salts and PARP inhibitors and the limitations of existing genomic tests, there is a need to develop 188 novel frameworks to guide the current standard-of-care for HRD tumors (23).

189

190 Recently, deep learning AI approaches have demonstrated the ability to detect genomic

191 alterations directly from H&E images, including biomarkers related to patient outcome, which

192 could be leveraged for pre-screening tests. While demonstrating a high-concordance in

193 predicting genomic HRD, DeepHRD was also capable of directly predicting individual patient

10

194	outcome to HRD-targeted therapy using response and progression-free survival based on
195	RECIST criteria. Furthermore, DeepHRD provided better prediction of clinical response and
196	progression-free survival to platinum therapies than existing genomic biomarkers. Notably, our
197	approach captured patients with BRCA1/2 wild-type tumors who responded to platinum therapy,
198	thus, identifying 4-fold more responders than BRCA1/2 mutation-testing alone (Fig. 2d). These
199	results demonstrate that molecular assays, traditionally used for assessing HRD in a clinical
200	setting, can be substituted and/or complemented with AI-based deep learning models for
201	predicting clinical response from conventional diagnostic histopathological slides.
202	
203	While there has been a recent explosion of deep learning methods applied to digital pathology
204	(28), the immediate translation into clinical practice has been limited by the high costs associated
205	with acquiring infrastructure for routinely capturing digital H&E slides (27, 39). With the
206	development of tertiary scanning services seeking to alleviate these overhead costs, a recent
207	study has shown a potential alternative approach for utilizing analogous deep learning AI-models
208	to make predictions from photographs taken directly by hand-held devices $(40)$ . In coordination
209	with the optimization of lightweight deep learning architectures, using images from a
210	smartphone attached to the ocular lens of a conventional light microscope promises inexpensive,
211	efficient, and accurate deep-learning read-outs within seconds of preparing an H&E slide. By
212	relying on smartphone microscopy images, this transition would provide AI-based diagnostic
213	solutions for equitable and efficient clinical management for cancer patients across globally
214	diverse socioeconomic groups.
215	

### 216 FIGURE LEGENDS

## 217 Fig. 1. Multi-resolution convolutional neural network architecture to detect homologous 218 recombination deficiency from histopathological tissue slides. a) Training a DeepHRD model 219 for detecting homologous recombination deficiency (HRD) from whole-slide images (WSIs). For 220 each WSI, a single prediction score is estimated based on the detection of HRD. Specifically, 221 each WSI undergoes preprocessing and quality control (1). This module consists of tissue 222 segmentation, filtering for non-focused tissue, and final tiling of regions that contain tissue at 5x 223 magnification. All tiles for a single image are processed through the first multiple instance 224 learning (MIL) ResNet18 convolutional neural network (2). This architecture uses the average of 225 the top 25 predicted tile scores as the WSI predicted score. Dropout is incorporated into the fully 226 connected layers in the feature extraction module to reduce overfitting during training. The same 227 dropout technique is also incorporated during inference to simulate Monte Carlo dropout used to 228 calculate confidence intervals in the final WSI prediction. The tile feature vectors from the 229 penultimate layer of the feature extraction are used to automatically select regions of interest 230 (ROI) from the original WSI for additional assessment (3). The feature vectors are reduced in 231 dimensions using principal component analysis and a custom k-means clustering module is used 232 to determine the optimal number of clusters per sample. The selected tiles are then resampled at 233 a 20x magnification (4). These sets of tiles are used to train a second MIL-ResNet18 model (5) 234 using an identical architecture to the one previously used in (2). The average predictions across 235 both models are aggregated for a single WSI (6). The resulting distribution of scores are used to 236 calculate confidence intervals and establish a threshold of confidence for a final prediction. b) 237 Using a trained DeepHRD model for HRD prediction from a single whole-slide image.

238 DeepHRD produces a final prediction score for individual patient biopsies, with a

239 computational-based diagnosis for subsequent clinical action.

240

#### 241 Fig. 2. DeepHRD for detecting homologous recombination deficiency and predicting

response to treatment in primary and metastatic breast cancer. *a*) The receiver operating

243 characteristic curves (ROCs) for classifying homologous recombination deficiency (HRD) in the

TCGA held-out set and the independent set of primary breast cancers, encompassing the

independent CPTAC and METABRIC primary breast cancer cohorts. b) Representative TCGA

tissue slides are shown for both HRD and homologous recombination proficient (HRP) samples

across multiple breast cancer subtypes along with the resulting predictions for each segmented

tile at 5x and 20x resolutions. c) ROCs for formalin-fixed paraffin-embedded (FFPE) diagnostic

249 model in the TCGA held-out set and for classifying metastatic breast cancer (MBC) patients who

are complete responders to platinum therapy. *d*) Kaplan-Meier survival curves for MBC patients

treated with platinum chemotherapy separated by DeepHRD model predictions (*left*), *BRCA1/2* 

252 mutation status (*middle*), and SBS3 activity as detected by SigMA (*right*). Q-values are corrected

after considering breast cancer subtype, age at diagnosis, and the standard-of-care binary HRD

254 classification score  $\geq$  42 (*i.e.*, HRD score). Cox regression showing the log<sub>10</sub>-transformed hazard

ratios are shown with their 95% confidence intervals (*bottom*). Q-values less than or equal to

256 0.05 are annotated with \* while q-values above 0.05 are annotated with n.s. (*i.e.*, non-

257 significant).

258

259 Fig. 3. DeepHRD transfer learning in ovarian cancer for predicting response to platinum

260 treatment. *a*) Schematic demonstrating the transfer learning method to train an ovarian

261	homologous recombination deficiency (HRD) model from whole-slide H&E image (WSI) using
262	a pretrained breast DeepHRD model. The pretrained flash-frozen breast model is used to initiate
263	the weights and biases of all parameters in the ovarian model. HRD-scores are calculated from
264	SNP6 genotyping microarray by deriving loss of heterozygosity (LOH), large-scale transitions
265	(LST), and telomeric allelic imbalance (TAI). b) Kaplan-Meier survival curves comparing the
266	outcomes of patients treated with platinum chemotherapy split by the prediction of the
267	DeepHRD transfer learning model. c) Kaplan-Meier survival curves comparing the outcomes of
268	platinum-treated patients split by the base model predictions with no transfer learning applied
269	(left), BRCA1/2 mutation status (middle), and SBS3 activity as detected by SigMA (right). Q-
270	values are corrected after considering ovarian cancer stage, age at diagnosis, and the standard-of-
271	care binary HRD classification score $\geq 63$ ( <i>i.e.</i> , HRD score). Cox regression showing the log10-
272	transformed hazard ratios are shown with their 95% confidence intervals (bottom). Q-values less
273	than or equal 0.05 are annotated with * while q-values above 0.05 are annotated with n.s. ( <i>i.e.</i> ,
274	non-significant).

275

### 276 Acknowledgements

- 277 The results shown are in part based upon data generated by the TCGA Research Network:
- 278 <u>http://cancergenome.nih.gov/</u>. Additional data used in this publication were generated by the
- 279 Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Molecular Taxonomy of
- 280 Breast Cancer International Consortium (METABRIC). The computational analyses reported in
- this manuscript have utilized the Triton Shared Computing Cluster at the San Diego
- 282 Supercomputer Center of UC San Diego.

283

#### 284 Funding

285 This work was funded by a US National Institutes of Health grant R01ES032547 and UC San

286 Diego start-up funding to LBA.

287

#### 288 Author contributions

ENB and LBA designed the overall study. ENB performed all analyses with help from AA,

290 MDG, LG, SML, SL, and LBA. Specifically, AA assisted in the calculation and interpretation of

the genomically-derived HRD scores. MDG assisted in the processing of the digital images. LG

- and SL assisted in the analysis and interpretation of the metastatic breast cancer cohort. SML
- assisted in the interpretation and analysis of the survival and clinical associations. ENB and LBA
- wrote the manuscript with help and input from all other authors. All authors read and approved
- the final manuscript.
- 296
- 297
- 298

### 299 Competing interests

LBA is a compensated consultant and has equity interest in io9, LLC and Genome Insight. His 300 spouse is an employee of Biotheranostics, Inc. SML is a co-founder and has equity interest in io9, 301 LLC. AA and LBA declare U.S. provisional patent application with serial numbers 63/366,392 for 302 303 detecting homologous recombination deficiency from genomics data. ENB, SML, and LBA 304 declare U.S. provisional patent application with serial numbers 63/269,033 for artificial 305 intelligence architecture for predicting cancer biomarkers. All other authors declare they have no 306 known competing financial interests or personal relationships that could have appeared to 307 influence the work reported in this paper.

308

### 309 Data and materials availability

310 All datasets utilized in this study were previously generated and publicly available. These data can

311 be access through the accession codes listed in **Supplementary Materials**. The sources code for

312 DeepHRD will be made publicly available upon the publication of this study.

### 313 **REFERENCES**

- R. L. Schilsky, D. L. Longo, Closing the Gap in Cancer Genomic Testing. *N Engl J Med* 387, 2107-2110 (2022).
- J. Setton *et al.*, Synthetic Lethality in Cancer Therapeutics: The Next Generation. *Cancer Discov* 11, 1626-1635 (2021).
- R. Prakash, Y. Zhang, W. Feng, M. Jasin, Homologous recombination and human health:
   the roles of BRCA1, BRCA2, and associated proteins. *Cold Spring Harb Perspect Biol* 7, a016600 (2015).
- 321 4. E. M. John *et al.*, Prevalence of pathogenic BRCA1 mutation carriers in 5 US
  322 racial/ethnic groups. *JAMA* 298, 2869-2876 (2007).
- 5. K. E. Malone *et al.*, Prevalence and predictors of BRCA1 and BRCA2 mutations in a
  population-based study of breast cancer in white and black American women ages 35 to
  64 years. *Cancer Res* 66, 8297-8308 (2006).
- B. P. Polak *et al.*, A mutational signature reveals alterations underlying deficient
  homologous recombination repair in breast cancer. *Nat Genet* 49, 1476-1486 (2017).
- H. Davies *et al.*, HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. *Nat Med* 23, 517-525 (2017).
- 8. S. Nik-Zainal *et al.*, Landscape of somatic mutations in 560 breast cancer whole-genome
  sequences. *Nature* 534, 47-54 (2016).
- 332 9. L. B. Alexandrov *et al.*, Signatures of mutational processes in human cancer. *Nature* 500, 415-421 (2013).
- L. B. Alexandrov *et al.*, The repertoire of mutational signatures in human cancer. *Nature*578, 94-101 (2020).
- 336 11. G. Peng *et al.*, Genome-wide transcriptome profiling of homologous recombination DNA
  337 repair. *Nat Commun* 5, 3361 (2014).
- M. J. Larsen *et al.*, Classifications within molecular subtypes enables identification of
   BRCA1/BRCA2 mutation carriers by RNA tumor profiling. *PLoS One* 8, e64268 (2013).
- J. G. Tate *et al.*, COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids Res* 47, D941-D947 (2019).
- 342 14. D. C. Gulhan, J. J. Lee, G. E. M. Melloni, I. Cortes-Ciriano, P. J. Park, Detecting the
  343 mutational signature of homologous recombination deficiency in clinical samples. *Nat*344 *Genet* 51, 912-919 (2019).
- N. Y. L. Ngoi, D. S. P. Tan, The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? *ESMO Open* 6, 100144
  (2021).
- 348 16. M. L. Telli *et al.*, Homologous Recombination Deficiency (HRD) Score Predicts
  349 Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple350 Negative Breast Cancer. *Clin Cancer Res* 22, 3764-3773 (2016).
- 351 17. G. M. Frampton *et al.*, Development and validation of a clinical cancer genomic profiling
  352 test based on massively parallel DNA sequencing. *Nat Biotechnol* **31**, 1023-1031 (2013).
- 18. E. H. Stover, K. Fuh, P. A. Konstantinopoulos, U. A. Matulonis, J. F. Liu, Clinical assays
  for assessment of homologous recombination DNA repair deficiency. *Gynecol Oncol*159, 887-898 (2020).
- 356 19. A. L. Heeke *et al.*, Prevalence of Homologous Recombination-Related Gene Mutations
  357 Across Multiple Cancer Types. *JCO Precis Oncol* 2018, (2018).

358 359 360	20.	H. Wen <i>et al.</i> , Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer. <i>BMC Cancer</i> <b>22</b> , 550 (2022).
361	21.	L. Nguyen, W. M. M. J, A. Van Hoeck, E. Cuppen, Pan-cancer landscape of homologous
362	21.	recombination deficiency. <i>Nat Commun</i> <b>11</b> , 5584 (2020).
363	22.	B. M. Norquist <i>et al.</i> , Mutations in Homologous Recombination Genes and Outcomes in
364	<i>LL</i> .	Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology
365		Group Study. <i>Clin Cancer Res</i> <b>24</b> , 777-783 (2018).
366	23.	F. Perez-Villatoro <i>et al.</i> , Optimized detection of homologous recombination deficiency
367	23.	improves the prediction of clinical outcomes in cancer. <i>NPJ Precis Oncol</i> <b>6</b> , 96 (2022).
368	24.	E. Rodler <i>et al.</i> , Cisplatin with veliparib or placebo in metastatic triple-negative breast
369	21.	cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-
370		blind, placebo-controlled, phase 2 trial. <i>Lancet Oncol</i> <b>24</b> , 162-174 (2023).
371	25.	W. Park <i>et al.</i> , Genomic Methods Identify Homologous Recombination Deficiency in
372	20.	Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clin Cancer Res</i> <b>26</b> , 3239-
373		3247 (2020).
374	26.	P. A. Ascierto, C. Bifulco, G. Palmieri, S. Peters, N. Sidiropoulos, Preanalytic Variables
375	201	and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical
376		Analysis. J Mol Diagn 21, 756-767 (2019).
377	27.	J. N. Kather <i>et al.</i> , Deep learning can predict microsatellite instability directly from
378		histology in gastrointestinal cancer. Nat Med 25, 1054-1056 (2019).
379	28.	A. Echle <i>et al.</i> , Deep learning in cancer pathology: a new generation of clinical
380		biomarkers. Br J Cancer 124, 686-696 (2021).
381	29.	G. Campanella et al., Clinical-grade computational pathology using weakly supervised
382		deep learning on whole slide images. Nat Med 25, 1301-1309 (2019).
383	30.	J. Li et al., A multi-resolution model for histopathology image classification and
384		localization with multiple instance learning. Comput Biol Med 131, 104253 (2021).
385	31.	T. Lazard <i>et al.</i> , Deep learning identifies morphological patterns of homologous
386		recombination deficiency in luminal breast cancers from whole slide images. Cell Rep
387		<i>Med</i> <b>3</b> , 100872 (2022).
388	32.	N. Cancer Genome Atlas, Comprehensive molecular portraits of human breast tumours.
389		<i>Nature</i> <b>490</b> , 61-70 (2012).
390	33.	Z. Sztupinszki et al., Migrating the SNP array-based homologous recombination
391		deficiency measures to next generation sequencing data of breast cancer. NPJ Breast
392		<i>Cancer</i> <b>4</b> , 16 (2018).
393	34.	H. Takaya, H. Nakai, S. Takamatsu, M. Mandai, N. Matsumura, Homologous
394		recombination deficiency status-based classification of high-grade serous ovarian
395		carcinoma. Sci Rep 10, 2757 (2020).
396	35.	Z. Sztupinszki et al., Comparative Assessment of Diagnostic Homologous
397		Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer. Clin
398		<i>Cancer Res</i> <b>27</b> , 5681-5687 (2021).
399	36.	L. Galland et al., Efficacy of platinum-based chemotherapy in metastatic breast cancer
400		and HRD biomarkers: utility of exome sequencing. NPJ Breast Cancer 8, 28 (2022).
401	37.	N. C. I. C. P. T. A. C. (CPTAC), The Clinical Proteomic Tumor Analysis Consortium
402		Breast Invasive Carcinoma Collection (CPTAC-BRCA) (Version 1) [Data set]. The
403		Cancer Imaging Archive, (2020).

- 404 38. C. Curtis *et al.*, The genomic and transcriptomic architecture of 2,000 breast tumours
  405 reveals novel subgroups. *Nature* 486, 346-352 (2012).
- 406 39. V. Baxi, R. Edwards, M. Montalto, S. Saha, Digital pathology and artificial intelligence in translational medicine and clinical practice. *Mod Pathol* 35, 23-32 (2022).
- 408 40. M. Y. Lu *et al.*, Data-efficient and weakly supervised computational pathology on whole-409 slide images. *Nat Biomed Eng* **5**, 555-570 (2021).

410

Figure 1. Multi-resolution convolutional neural network architecture to detect homologous recombination deficiency from histopathological tissue slides **a** 



b





### Individualized Patient Recommendation



Figure 2. DeepHRD for detecting homologous recombination deficiency and predicting response to treatment in primary and metastatic breast cancer



Age

Subtype

HRD score

BRCA1/2

-1.2 -1.0 -0.8 ΠĊ.

-0.2 0.0 0.2

-0.6 -0.4

og10(HR)

Age

Subtype

HRD score

SBS3

-1.2 -1.0

-0.8 -0.6 -0.4 -0.2 0.0

log10(HR)

0.2

ı.s

n.s



0.0

0.0



Figure 3. DeepHRD transfer learning in ovarian cancer for predicting response to platinum treatment



С

#### TCGA Platinum-treated Ovarian Cancer

